Pharmafile Logo

The risk of replicating social bias in synthetic patient data – The need for human intelligence partnered with AI

Authored by Paul Reed and Anabelle Gall

- PMLiVE

As we move forward in 2024, the healthcare industry has embraced the idea that AI-generated synthetic patients are here for the long haul. The remarkable ability to utilize artificial patients that mimic real-world patient data addresses crucial unmet needs, making it nearly impossible to envision a future healthcare industry without widespread usage and integration of synthetic patients.

However, we must strike a delicate balance between integrating AI tools into market research and acknowledging the invaluable role of human intelligence in understanding, verifying, supervising and analysing insights. In this article, we delve into the compelling arguments surrounding the opportunities and risks associated with the utilization of AI-generated synthetic patients in healthcare market research.

Read the full article here. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Case study: How segmentation of treaters guided a novel product launch in the allergy space

Find out how we helped our client to obtain an intuitive and actionable segmentation in order to drive market shaping activities ahead of their product launch aimed at the treatment…

Article: War in the Blood – The battle takes shape in the burgeoning European oncology CAR-T market access space

Tania Rodrigues investigates the market access and commercialization potential for manufacturers of CAR-T therapies in the latest issue of pharmaphorum’s Deep Dive.

Research Partnership wins prestigious 2023 BOBI Award

We are delighted to announce Research Partnership were announced the winners in the ‘Creative Fieldwork Team of the Year’ category at the BHBIA’s Best of Business Intelligence (BOBI) Awards.

Case study: How we provided in-depth knowledge of electrosurgical generators among target segments and settings in the US market

Find out how we helped our client to identify clinician roles and responsibilities, pain points and drivers and barriers with respect to a current medical device.

Research Partnership launches Access CGT

Research Partnership’s specialist market access team have launched Access CGT, a new syndicated access and policy tracker providing surveillance of the cell and gene therapy space.Read more

New syndicated reports now available

Living with CD, PsO, IPF & PF-ILD 2023

Article: Could combating stigma increase the uptake of PrEP and finally end the HIV epidemic?

In this article we explore what more could be done by the pharmaceutical industry to help prevent the spread of HIV infection worldwide.

Webcast: China Update 2023: How will recent developments impact your brand’s success?

Register for this live webinar in which emerging market experts provide an update regarding the implications of changing demographics and the healthcare landscape.

Webcast: How to improve the patient journey through an effective engagement and activation strategy

Watch part two in a series, Evolving Patient Journeys, in which experts from across Inizio explore why, despite best intentions, patient engagement solutions can fall short of expectations.

Webcast: Evolving Patient Journeys – How to generate deeper insights in a changing healthcare landscape

Watch part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years.